Compare Fresenius Kabi Onco. with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs DIVIS LABORATORIES - Comparison Results

FRESENIUS KABI ONCO.     Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. DIVIS LABORATORIES FRESENIUS KABI ONCO./
DIVIS LABORATORIES
 
P/E (TTM) x 22.1 58.2 38.0% View Chart
P/BV x 3.1 15.6 20.0% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 FRESENIUS KABI ONCO.   DIVIS LABORATORIES
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
DIVIS LABORATORIES
Mar-19
FRESENIUS KABI ONCO./
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1761,639 10.7%   
Low Rs791,115 7.0%   
Sales per share (Unadj.) Rs37.7186.3 20.2%  
Earnings per share (Unadj.) Rs5.151.0 10.0%  
Cash flow per share (Unadj.) Rs6.757.3 11.7%  
Dividends per share (Unadj.) Rs016.00 0.0%  
Dividend yield (eoy) %01.2 0.0%  
Book value per share (Unadj.) Rs42.5261.8 16.3%  
Shares outstanding (eoy) m158.23265.47 59.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.47.4 45.7%   
Avg P/E ratio x25.027.0 92.4%  
P/CF ratio (eoy) x18.924.0 78.8%  
Price / Book Value ratio x3.05.3 56.9%  
Dividend payout %031.4 0.0%   
Avg Mkt Cap Rs m20,135365,592 5.5%   
No. of employees `0001.211.8 9.7%   
Total wages/salary Rs m7035,423 13.0%   
Avg. sales/employee Rs Th5,176.24,175.1 124.0%   
Avg. wages/employee Rs Th610.4457.7 133.4%   
Avg. net profit/employee Rs Th699.61,141.8 61.3%   
INCOME DATA
Net Sales Rs m5,96349,463 12.1%  
Other income Rs m181,556 1.2%   
Total revenues Rs m5,98151,019 11.7%   
Gross profit Rs m1,43018,718 7.6%  
Depreciation Rs m2581,689 15.3%   
Interest Rs m-2635 -74.3%   
Profit before tax Rs m1,21618,551 6.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m3425,023 6.8%   
Profit after tax Rs m80613,527 6.0%  
Gross profit margin %24.037.8 63.4%  
Effective tax rate %28.127.1 103.9%   
Net profit margin %13.527.3 49.4%  
BALANCE SHEET DATA
Current assets Rs m5,10246,501 11.0%   
Current liabilities Rs m2,3858,468 28.2%   
Net working cap to sales %45.676.9 59.2%  
Current ratio x2.15.5 38.9%  
Inventory Days Days150131 114.7%  
Debtors Days Days11386 132.0%  
Net fixed assets Rs m5,14825,797 20.0%   
Share capital Rs m158531 29.8%   
"Free" reserves Rs m6,55668,962 9.5%   
Net worth Rs m6,73269,493 9.7%   
Long term debt Rs m9520-   
Total assets Rs m10,38880,383 12.9%  
Interest coverage x-45.8531.0 -8.6%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.60.6 93.3%   
Return on assets %7.516.9 44.5%  
Return on equity %12.019.5 61.5%  
Return on capital %14.626.7 54.6%  
Exports to sales %74.50-   
Imports to sales %24.824.6 100.6%   
Exports (fob) Rs m4,441NA-   
Imports (cif) Rs m1,47712,187 12.1%   
Fx inflow Rs m5,29841,238 12.8%   
Fx outflow Rs m1,77212,405 14.3%   
Net fx Rs m3,52528,833 12.2%   
CASH FLOW
From Operations Rs m1,2749,543 13.4%  
From Investments Rs m-1,204-6,854 17.6%  
From Financial Activity Rs m-196-2,459 8.0%  
Net Cashflow Rs m-126230 -55.0%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 11.8 2.5%  
FIIs % 9.6 19.0 50.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 17.2 52.9%  
Shareholders   42,599 31,796 134.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   ABBOTT INDIA  JUBILANT PHARMOVA   ELDER PHARMA  PFIZER  ALKEM LABORATORIES  

Compare FRESENIUS KABI ONCO. With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Falls 471 Points, Nifty Ends Below 14,700; Tata Steel & JSW Steel Top Losers(Closing)

Indian share markets witnessed selling pressure throughout the day today and ended lower.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (3QFY21); Net Profit Up 27.9% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 27.9% YoY). Sales on the other hand came in at Rs 17 bn (up 19.1% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY21); Net Profit Up 84.1% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY20); Net Profit Up 35.4% (Quarterly Result Update)

Jun 8, 2020 | Updated on Jun 8, 2020

For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY20); Net Profit Down 4.9% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 4.9% YoY). Sales on the other hand came in at Rs 14 bn (up 3.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (2QFY20); Net Profit Down 10.3% (Quarterly Result Update)

Nov 11, 2019 | Updated on Nov 11, 2019

For the quarter ended September 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 10.3% YoY). Sales on the other hand came in at Rs 14 bn (up 12.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. - FDC COMPARISON

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS